MCC
NTLA icon

Money Concepts Capital’s Intellia Therapeutics NTLA Stock Holding History

Money Concepts Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-200
Closed -$6.98K – 2047
2022
Q4 		$6.98K Buy
200
+100
+100% +$4.75K ﹤0.01% 2193
2022
Q3 		$6K Hold
100
– – ﹤0.01% 1178
2022
Q2 		$5K Hold
100
– – ﹤0.01% 1176
2022
Q1 		$7K Buy
+100
New +$8.47K ﹤0.01% 2080

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Money Concepts Capital's NTLA Position: Q1 2023 in Review

Money Concepts Capital sold out of Intellia Therapeutics (NTLA) in Q1 2023, closing a stake of 200 shares — an estimated $6.98K sold.

Money Concepts Capital first reported a position in NTLA in Q1 2022 and held it in 4 quarters. The position peaked at $7K in Q1 2022. 290 funds tracked by Wall St. Rank hold NTLA as of Q1 2023.

  • Money Concepts Capital reported no remaining Intellia Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Money Concepts Capital sold 200 Intellia Therapeutics shares in Q1 2023, an estimated $6.98K.
  • Money Concepts Capital first reported a position in Intellia Therapeutics in Q1 2022 and held it in 4 quarters.
  • Money Concepts Capital's Intellia Therapeutics position peaked at $7K in Q1 2022.
  • 290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2023.

Based on Money Concepts Capital's 13F filing for Q1 2023, filed 1 May 2023.